ProShare Advisors LLC Purchases 8,293 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

ProShare Advisors LLC increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 59.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,152 shares of the specialty pharmaceutical company’s stock after acquiring an additional 8,293 shares during the period. ProShare Advisors LLC’s holdings in Supernus Pharmaceuticals were worth $593,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Supernus Pharmaceuticals by 2.3% during the 4th quarter. Vanguard Group Inc. now owns 6,214,731 shares of the specialty pharmaceutical company’s stock valued at $179,854,000 after purchasing an additional 142,551 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Supernus Pharmaceuticals by 12.1% during the second quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock valued at $76,690,000 after buying an additional 309,966 shares during the last quarter. Stephens Investment Management Group LLC raised its position in Supernus Pharmaceuticals by 11.7% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,904,864 shares of the specialty pharmaceutical company’s stock worth $55,127,000 after acquiring an additional 200,166 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Supernus Pharmaceuticals by 26.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock worth $45,077,000 after acquiring an additional 351,900 shares during the last quarter. Finally, Pacer Advisors Inc. grew its position in shares of Supernus Pharmaceuticals by 100,186.3% during the 2nd quarter. Pacer Advisors Inc. now owns 1,349,854 shares of the specialty pharmaceutical company’s stock valued at $36,109,000 after acquiring an additional 1,348,508 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Piper Sandler downgraded Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $41.00 to $36.00 in a research report on Wednesday, September 11th.

Supernus Pharmaceuticals Trading Down 0.1 %

Shares of NASDAQ:SUPN opened at $30.75 on Monday. The company has a 50-day moving average price of $32.27 and a 200 day moving average price of $30.39. Supernus Pharmaceuticals, Inc. has a 12 month low of $21.99 and a 12 month high of $35.44. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -106.03 and a beta of 0.88.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 EPS for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). The firm had revenue of $168.30 million for the quarter, compared to analysts’ expectations of $148.83 million. Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. Supernus Pharmaceuticals’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.02) earnings per share. As a group, equities analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.